Sign In
Buy DTIL
$6.04
-0.280 (-4.43%)
At Close: Jun 03, 2026
Precision BioSciences: Q1 Earnings Insights
12:52pm, Friday, 15'th May 2020
Shares of Precision BioSciences (NASDAQ:DTIL) rose 8.2% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 73.87% year over year to ($0.52), which we
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
12:15pm, Friday, 15'th May 2020
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 1.89% and 34.71%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update
11:00am, Friday, 15'th May 2020
Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL PBCAR0191 Phase 1/2a Trial is Progressing with Updated Interim Data.
Roche's Upcoming Phase 2 TIGIT Results At ASCO Could Read Through To Compugen's COM902 TIGIT Candidate
05:41pm, Tuesday, 12'th May 2020
Roche's (Genentech) Phase 2 clinical trial results for its TIGIT candidate (tiragolumab) in non-small cell lung cancer will be presented for the first time at A
Autolus: A Highly Undervalued CAR-T Company
01:36pm, Tuesday, 12'th May 2020
AUTO1 is uniquely positioned among CD19-targeted CAR-T products due to its fast off-rate kinetics. AUTO1 has low rates of cytokine release syndrome with better
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q1 2020 Results - Earnings Call Transcript
04:51am, Tuesday, 12'th May 2020
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Q1 2020 Results Conference Call May 11, 2020 4:30 PM ET Company Participants Jayne Kauffman - Senior Executive Coor
2020 Insights on the Worldwide Induced Pluripotent Stem Cell Industry - ResearchAndMarkets.com
12:00am, Tuesday, 12'th May 2020
The
Infinity Pharmaceuticals Provides Company Update and First Quarter 2020 Financial Results
12:00am, Monday, 11'th May 2020
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2020 financial results and provided an update on the Company, includin
Precision BioSciences (DTIL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
04:30pm, Friday, 08'th May 2020
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Genome Editing Market Segments and Share Analysis Report by 2026
08:42am, Friday, 08'th May 2020
May 08, 2020 (CDN Newswire via Comtex) --
Facts & Factors Market Research added a recent report on "Genome Editing Market Technology (CRISPR (Clustered...
DURHAM, N.C., May 07, 2020 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering,.
Port Jackson Partners and Byron Pirola to join EY
06:00am, Thursday, 07'th May 2020
The storied boutique consulting firm will maintain separate operations as EY looks to beef up its strategy services.
Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
08:45pm, Tuesday, 28'th Apr 2020
DURHAM, N.C., April 28, 2020 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering,.
Portugal's Brisa owners sell 81% of motorway operator to investors' consortium
10:55am, Tuesday, 28'th Apr 2020
The two main owners of Portugal's Brisa, Jose de Mello conglomerate and London-based infrastructure fund Arcus, said on Tuesday they sold 81% of the country's main motorway operator to a consortium of
Will Precision BioSciences (DTIL) Report Negative Q1 Earnings? What You Should Know
04:31pm, Monday, 27'th Apr 2020
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
